DongKoo Bio & Pharma Co., Ltd. (KOSDAQ:006620)

DongKoo Bio & Pharma Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	5,555	25,372	15,713	12,514	19,557	4,881
Short-Term Investments	506.9	506.9	1,941	1,351	143.14	87.57
Trading Asset Securities	10,399	10,371	5,245	21,271	12,399	24,616
Cash & Short-Term Investments	16,461	36,250	22,898	35,136	32,100	29,585
Cash Growth	-29.94%	58.31%	-34.83%	9.46%	8.50%	168.63%
Accounts Receivable	22,575	19,876	19,879	18,503	15,774	17,455
Other Receivables	288.22	1,352	1,570	898.47	633.49	136.73
Receivables	26,034	23,953	22,449	19,402	16,408	17,592
Inventory	59,547	45,962	42,606	31,428	24,964	24,971
Prepaid Expenses	476.82	324.71	216.61	225.89	229.66	200.1
Other Current Assets	1,220	751.62	195.02	1,226	131.5	4.72
Total Current Assets	103,739	107,242	88,365	87,417	73,832	72,353
Property, Plant & Equipment	65,528	66,222	50,483	39,681	40,051	40,377
Long-Term Investments	71,137	50,419	39,800	33,619	35,498	26,495
Other Intangible Assets	5,473	13,172	10,903	9,010	3,048	2,081
Long-Term Accounts Receivable	-	-	-	-	-	16.66
Long-Term Deferred Tax Assets	3,797	3,162	291.5	6.95	-	-
Other Long-Term Assets	2,237	3,843	1,260	2,325	2,358	3,031
Total Assets	259,312	244,061	191,103	172,059	154,786	144,353
Accounts Payable	14,966	15,591	11,202	14,300	11,591	9,191
Accrued Expenses	11,156	11,337	10,274	9,637	6,496	4,683
Short-Term Debt	74,487	74,876	40,500	33,000	18,070	18,000
Current Portion of Long-Term Debt	1,750	-	-	-	5,000	-
Current Portion of Leases	631.52	681.03	842.63	567.83	453.23	523.99
Current Income Taxes Payable	1,072	3,325	1,638	2,576	1,978	915.59
Other Current Liabilities	8,102	9,441	8,863	5,963	6,434	7,194
Total Current Liabilities	112,163	115,251	73,318	66,044	50,022	40,508
Long-Term Debt	19,122	10,467	1,447	-	-	5,000
Long-Term Leases	434.37	616.95	1,014	754.22	770.27	219.01
Pension & Post-Retirement Benefits	0	0	277.09	0	205.81	0
Long-Term Deferred Tax Liabilities	4.1	8.89	4.5	140.93	2,315	3,034
Other Long-Term Liabilities	15,455	12,269	4,596	3,015	1,350	939.53
Total Liabilities	147,178	138,613	80,658	69,953	54,662	49,701
Common Stock	14,232	14,232	14,232	14,232	14,232	4,802
Additional Paid-In Capital	33,562	33,063	33,063	33,063	33,063	42,569
Retained Earnings	74,689	67,320	69,735	61,675	57,158	49,727
Treasury Stock	-10,545	-10,545	-7,137	-7,058	-4,062	-2,065
Comprehensive Income & Other	142.46	1,261	507.18	193.39	-266.18	-380.89
Total Common Equity	112,081	105,332	110,400	102,106	100,124	94,653
Minority Interest	53.22	116.03	44.92	-	-	-
Shareholders' Equity	112,134	105,448	110,445	102,106	100,124	94,653
Total Liabilities & Equity	259,312	244,061	191,103	172,059	154,786	144,353
Total Debt	96,425	86,641	43,804	34,322	24,294	23,743
Net Cash (Debt)	-79,964	-50,391	-20,906	813.88	7,806	5,842
Net Cash Growth	-	-	-	-89.57%	33.61%	-
Net Cash Per Share	-2912.53	-1845.19	-756.89	29.32	276.23	206.49
Filing Date Shares Outstanding	27.04	27.04	27.61	27.62	28.04	28.29
Total Common Shares Outstanding	27.04	27.04	27.61	27.62	28.04	28.29
Working Capital	-8,424	-8,009	15,046	21,374	23,811	31,844
Book Value Per Share	4144.68	3895.10	3998.84	3696.33	3570.78	3345.63
Tangible Book Value	106,608	92,160	99,497	93,096	97,076	92,572
Tangible Book Value Per Share	3942.28	3408.02	3603.92	3370.16	3462.08	3272.08
Land	13,262	13,262	10,849	10,849	10,584	10,584
Buildings	27,913	39,356	29,667	27,353	26,899	26,120
Machinery	11,195	30,310	19,768	17,741	17,813	16,838
Construction In Progress	8,237	7,823	10,694	1,451	887.9	844.54

Source: S&P Global Market Intelligence. Standard template. Financial Sources.